AbbVie: Hyperparathyroidism, Secondary trials

The registry lists 13 Hyperparathyroidism, Secondary studies with AbbVie as lead sponsor. 0 are open to participants now and 12 have results posted.

Phase 3 3Phase 4 1No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)TerminatedNCT04064827Phase 3Results posted
• A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant PatientsCompletedNCT01506947Phase 4Results posted
• Observational Program of Zemplar in Patients With End Stage Chronic Kidney Disease and Parathyroid Disorder on Hemodialysis in the Russian FederationCompletedNCT01401478Results posted
• A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or HemodialysisCompletedNCT01382212Phase 3Results posted
• Quality of Life in Greek Hemodialysis Patients Receiving Zemplar IntravenousCompletedNCT01368042Results posted
• Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary HyperparathyroidismCompletedNCT01341782Phase 3Results posted
• Study to Assess Patient Management Practices and Quality of Life With Paricalcitol Capsules in the Treatment of Secondary Hyperparathyroidism in Stage 3-5 Chronic Kidney Disease Patients Not Yet on DialysisCompletedNCT01265992Results posted
• Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT)CompletedNCT01224782Results posted
• Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical PracticeTerminatedNCT01134315Results posted
• Long-Term Therapy Outcomes When Treating Chronic Kidney Disease (CKD) Patients With Paricalcitol in German and Austrian Clinical PracticeCompletedNCT01083849Results posted
• Paricalcitol Oral Therapy in Predialysis CKD Patients. The Greek ExperienceCompletedNCT01083186Results posted
• Study to Evaluate the Effect of Intravenous (IV) Paricalcitol (Zemplar) on Cardiac Morbidity in Patients With Chronic Kidney Disease (CKD) Stage 5 Over 2 YearsCompletedNCT01073462Results posted
• A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving Selective Vitamin D Receptor Activator's for Prevention and Treatment of Secondary HyperparathyroidismCompletedNCT01149291